insulin sensitizer

     

pathologytreatmentpatient Demonstrated benefit and harm k      
diabetes type 2aleglitazarnot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2metforminnot classified

versus placebo or control

No demonstrated result for efficacy

2 trialsmeta-analysis
diabetes type 2metforminnot classified

versus SU or insulin

No demonstrated result for efficacy

metformin inferior to SU/Insulin in terms of CV events in UKPDS (vs SU or INS)

1 trialmeta-analysis
diabetes type 2metforminnot classified

versus Sulfonylureas

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2pioglitazonenot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2pioglitazonenot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2pioglitazonenot classified

versus placebo or control

No demonstrated result for efficacy

pioglitazone inferior to placebo in terms of serious heart failure in PROactive, 2005

4 trialsmeta-analysis
diabetes type 2pioglitazonenot classified

versus standard glucose-lowering drugs

No demonstrated result for efficacy

pioglitazone inferior to sulfonylurea in terms of serious heart failure in OPI-504

13 trialsmeta-analysis
diabetes type 2rosiglitazonenot classified

versus

No demonstrated result for efficacy

1 trialmeta-analysis
diabetes type 2rosiglitazonenot classified

versus standard glucose-lowering drugs

No demonstrated result for efficacy

rosiglitazone inferior to standard glucose-lowering drugs in terms of Bone fractures in RECORD, 2009

rosiglitazone inferior to standard glucose-lowering drugs in terms of HF death or hospitalization in RECORD, 2009

rosiglitazone inferior to standard glucose-lowering drugs in terms of heart failure in RECORD, 2009

rosiglitazone inferior to standard glucose-lowering drugs in terms of serious heart failure in RECORD, 2009

41 trialsmeta-analysis